Compare Novavax Inc (NVAX) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs ABRDN Physical Gold Shares ETF — how do they compare? Novavax Inc trades at $12.64 (market cap $1.82B), while ABRDN Physical Gold Shares ETF trades at $39.96 (market cap $7.03B). The key difference: ABRDN Physical Gold Shares ETF is far larger — about 3.9× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and ABRDN Physical Gold Shares ETF for 57 Days on average.
| NVAX | SGOL | |
|---|---|---|
Market Cap | $1.82B | $7.03B |
Volume | 6,198,505 | 2,350,550 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $12.56 | $51.41 |
52-Week Low | $6.22 | $37.54 |
Typical Hold Time | 59 Days | 57 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
SGOL trades at $39.81 with a 2.02% daily gain amid mixed technical signals. The overall technical picture remains bearish with moving averages indicating selling pressure, though oscillators show neutral momentum. Recent news highlights gold's sensitivity to Treasury yields and Federal Reserve policy expectations, with prices facing headwinds from rising rates but finding some support from inflation concerns and geopolitical tensions.
The outlook for SGOL is cautious with technical indicators favoring bearish momentum, while fundamental drivers depend on macroeconomic factors. Investment opportunities exist if inflation persists or geopolitical risks escalate, but risks include further rate hikes and dollar strength. Wall Street sentiment is divided with some analysts projecting declines to $4,100 while others see potential for $5,000 by mid-2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
